Yifat Edrei1,2, Eitan Gross3,
Nathalie Corchia1, Elia Dery1, Shmuel Ben-Sasson4,
Rinat Abramovitch1,2
1The Goldyn Savad Inst. for Gene
Therapy, Hadassah Hebrew University Medical Center, Jerusalem, Israel; 2MRI/MRS
lab HBRC, Hadassah Hebrew University Medical Center, Jerusalem, Israel; 3Pediatric
Surgery, Hadassah Hebrew University Medical Center; 4Experimental
Medicine & Cancer Research, The Hebrew Universioty Hadassah Medical
School
Since
anti-angiogenic therapies may not lead to substantial tumor shrinkage, their
effect is better imaged using perfusion imaging rather than tumor size
measurement. Recently, we demonstrated the feasibility of Hemodynamic
Response Imaging (HRI), an fMRI method combined with hypercapnia and
hyperoxia, for monitoring changes in liver perfusion and hemodynamics. Here
we show that a novel anti-angiogenic drug (Hamsa) reduces colorectal liver
metastases growth and thus prolong mice survival. We assessed the therapeutic
efficacy by HRI and revealed two types of response. By utilizing HRI we
revealed the underlying mechanisim of Hamsa potential which hopefully would
improve the Hamsa therapeutic potency.
Keywords